Evidence map›Paper›PMID 20712481›Full record

ArticleViral immunology2010

Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes.

Nadine Jarasch-Althof, Nadine Wiesener, Michaela Schmidtke, Peter Wutzler, Andreas Henke

Abstract read
PubMed Publisher
In one paragraph

Article in Viral immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nadine Jarasch-AlthofDepartment of Virology and Antiviral Therapy, University Hospital, Friedrich Schiller University Jena, Jena, Germany.
Nadine Wiesener
Michaela Schmidtke
Peter Wutzler
Andreas Henke
Jena University Hospital · DEFriedrich Schiller University Jena · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coxsackievirus B3 (CVB3) is associated with several different acute and chronic forms of human disease, including myocarditis, aseptic meningitis, and pancreatitis. Moreover, CVB3 also infects immune cells like CD19+ B lymphocytes, but the viral uptake mechanism into these cells is not well understood. Therefore, primary murine and human CD19+ B cells were isolated by magnetic-activated cell separation technology and analyzed for virus receptor expression, antibody-dependent enhancement of viral infection, and different cellular surface proteins, that might be involved in mechanisms of viral uptake. Western blot analysis of these cells revealed no significant expression of the coxsackievirus-adenovirus receptor CAR. But incubation of CVB3 with serum dilutions, which exhibited binding but not neutralizing characteristics, increased viral uptake and replication significantly in a dose-dependent manner. Viral entry was reduced when Fc portions of immunoglobulins were blocked by protein A treatment. Moreover, the classical complement system rather than Fc-gamma-receptor-mediated mechanisms could be involved in viral uptake. Taken together, these data suggest an antibody-dependent enhancement of CVB3 infection of primary murine and human CD19+ B cells.

Indexed as

Antibody-Dependent EnhancementAnimalsAntibodies, ViralAntigens, CD19B-LymphocytesCells, CulturedCoxsackie and Adenovirus Receptor-Like Membrane ProteinCoxsackievirus InfectionsDose-Response Relationship, ImmunologicEnterovirus B, HumanHost-Pathogen InteractionsHumansImmune SeraMaleMiceMice, Inbred BALB CAntibodies, ViralAntigens, CD19CLMP protein, humanCLMP protein, mouseCoxsackie and Adenovirus Receptor-Like Membrane ProteinImmune SeraReceptors, Virus

Identifiers

PMID20712481
OpenAlexW2079686981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.